Microbot Medical Inc. has announced the receipt of a non-dilutive grant from the Israel Innovation Authority, amounting to NIS 2.15 million (approximately $630,000). This funding will enhance the company's manufacturing capabilities as it prepares for the commercialization of the LIBERTY® Endovascular Robotic System, pending marketing clearance from the U.S. FDA. The grant, awarded solely to Microbot Medical, recognizes the company's recent achievements and the potential market impact of its single-use, disposable robotic system. Currently, the LIBERTY® System is an investigational device awaiting FDA 510(k) clearance and is not yet available for sale in the U.S.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。